CStone Pharmaceuticals-Jerry Pharmaceutical (09966): KN026 key Phase II/III clinical trial interim analysis achieves primary PFS endpoint.

Sinotrans Financial APP news, Conine Jeritzer Pharmaceuticals - B (09966) announced that the company's collaboration with Shanghai Jinmant Bio-technology Co., Ltd., a subsidiary of China Resources Pharmaceutical Group Limited (01093), in developing KN026 (KN026-001) for the second-line and above treatment of HER2-positive GC (including GEJ) has completed the first interim analysis, and the results of the interim analysis have achieved the primary endpoint of PFS.